Efficacy of Inhaled Ciclesonide for Outpatient Treatment with Symptomatic COVID-19
jamanetwork.com
The results of this randomized clinical trial demonstrated that ciclesonide did not achieve the primary efficacy end point of reduced time to alleviation of all COVID-19–related symptoms.
A total of 413 participants were screened and 400 (96.9%) were enrolled and randomized.
The median time to alleviation of all COVID-19–related symptoms was 19.0 days in the ciclesonide arm and 19.0 days in the placebo arm.
There was no difference in resolution of all symptoms by day 30.
Participants who were treated with ciclesonide had fewer subsequent emergency department visits or hospital admissions for reasons related to COVID-19.
No participants died during the study.
Related Stories
Related Books
